Izumabtreated MS individuals. Neurology 2008; 70:1150151. Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions beneath fingolimod therapy. Neurology 2012;79:2000003. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis sufferers treated with natalizumab. Ann Neurol 2006;59:74347. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124140. Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, on the web registry and platform for collaborative outcomes analysis in many sclerosis. Mult Scler 2006; 12:76974. O’Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: twoyear outcomes of a phase II extension study. Neurology 2009;72:739. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in sufferers with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:18691. Tubridy N, Behan PO, Capildeo R, et al. The effect of antialpha4 integrin antibody on brain lesion activity in MS: The UK Antegren Study Group. Neurology 1999;53:46672. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug vacation in clinical practice: an observational study in extremely active relapsing remitting several sclerosis sufferers. J Neurol Sci 2011;308:9802. Havla J, Gerdes LA, Meinl I, et al. Deescalation from natalizumab in various sclerosis: recurrence of illness activity in spite of switching to glatiramer acetate. J Neurol 2011;258:1665669.18.19.20.21.22.23.24.25.26.27.28.Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive numerous sclerosis soon after switching therapy from natalizumab to fingolimod. Mult Scler 2012;18:1650652. Kappos L, Bates D, Edan G, et al. Natalizumab therapy for a number of sclerosis: updated recommendations for patient choice and monitoring. Lancet Neurol 2011; ten:74558. Sempere AP, MartinMedina P, BerenguerRuiz L, et al.Buy1402664-68-9 Switching from natalizumab to fingolimod: an observational study.173252-76-1 Chemical name Acta Neurol Scand 2013;125:e6 10.PMID:23522542 Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing numerous sclerosis. N Engl J Med 2003;348:153. O’Connor PW, Goodman A, Kappos L, et al. Disease activity return for the duration of natalizumab remedy interruption in sufferers with a number of sclerosis. Neurology 2011;76:1858865. Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months following cessation of natalizumab therapy. Neurology 2009;72:39601. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsingremitting various sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012;18: 1640643. Held U, Heigenhauser L, Shang C, Kappos L, Polman C. Predictors of relapse rate in MS clinical trials. Neurology 2005;65:1769773. Fazekas F, Bajenaru O, Berger T, et al. How does fingolimod (Gilenya match within the remedy algorithm for extremely active relapsingremitting several sclerosis Front Neurol 2013;4:ten. Jeffery DR, Markowitz CE, Reder AT, WeinstockGuttman B, Tobias K. Fingolimod for the therapy of relapsing multiple sclerosis. Specialist Rev Neurother 2011; 11:16583. de Seze J, Ongagna JC, Collongues N, et al. Reduction on the washout time amongst natalizumab and fingolimod. Mult Scler 2013;19:1248.Love Significant Savings on NEW 2014 AAN Practice Management Webinars SubscriptionsThe American Academy of Neurology o.